Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Growth in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 916,352 shares, a growth of 331.5% from the August 31st total of 212,357 shares. Based on an average daily trading volume, of 2,311,369 shares, the short-interest ratio is presently 0.4 days. Currently, 0.8% of the shares of the company are sold short.

Indaptus Therapeutics Trading Down 5.6%

NASDAQ:INDP traded down $0.23 during mid-day trading on Friday, hitting $3.77. The company had a trading volume of 146,281 shares, compared to its average volume of 629,628. The business has a fifty day simple moving average of $1.91 and a 200-day simple moving average of $2.24. The firm has a market capitalization of $502.98 million, a price-to-earnings ratio of -0.60 and a beta of 1.17. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $8.57.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55.

Analyst Upgrades and Downgrades

Several analysts have recently commented on INDP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.